UnitedHealth's CEO acknowledged discontent with the health care system, but quickly shifted the blame elsewhere.

On the third day, drugmakers provided updates on precision medicines for cancer and Alzheimer's, and Grail talked about the launch of a new version of the Galleri test.

We recently compiled a list of the 12 Cheapest Stocks with Biggest Upside Potential. In this article, we are going to take a ...

In his first public comments since one of his executives was shot to death, UnitedHealth Group CEO Andrew Witty said the ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

UnitedHealth CEO Andrew Witty said on Thursday that healthcare in the U.S. needs to be "less confusing, less complex and less ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

Look deep into nature and then you will understand everything better.” The quote from Albert Einstein is generally deployed ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...